Survival Among Post-Operative Non-Small Cell Lung Cancer Patients Receiving Chemoradiotherapy; A Retrospective Analysis
Main Article Content
Abstract
Background: Despite being the second most frequent malignancy, lung cancer is the main reason for cancer-related fatalities. In this study, patients who underwent surgery for Non-Small Cell Lung Cancer and received adjuvant chemoradiotherapy will be evaluated.
Patients and Methods: The data of 123 eligible patients who were operated with the diagnosis of Non-Small Cell Lung Cancer between 2000 and 2020 and who were treated with adjuvant chemoradiotherapy were retrospectively analyzed.
Results: Of the 123 patients that were included in the study, 111 (90%) were males and 12 (10%) were females. The mean age was 62.11±8.92 (range:33-77) years. According to histological types, 65 (53%) patients were squamous cell carcinoma, 54 (44%) patients were adenocarcinoma and 4 (3%) patients were large cell carcinoma. Fifty-nine (48%) patients had undergone right lobectomy, 43 (35%) patients left lobectomy, 7 (6%) patients right pneumonectomy and 14 (11%) patients had left pneumonectomy. Mean OS time of all patients was 63.34±5.98 (51.62-75.07) months. One, 2, 3 and 5-year survival rates were 89.9%, 66.9%, 56.3% and 40.9%, respectively. There was a significant correlation between the T stage (p=0.05) of the disease and the chemotherapy protocol (p=0.046) and survival.
Conclusion: Complete surgical resection remains the most effective treatment for patients with operable Non-Small Cell Lung Cancer. The high risks of distant recurrence brought on by the presence of metastatic disease that went unnoticed prior to surgery, however, restrict the effectiveness of surgical resection. Therefore, postoperative chemoradiotherapy employing constrained areas and contemporary approaches can be advantageous.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Torre LA, Siegel RL, Jemal A. Lung Cancer Statistics. Adv Exp Med Biol 2016;893:1-19.
II. Kawachi R, Tsukada H, Nakazato Y, Takei H, Furuyashiki G, Koshi-ishi Y, et al. Early recurrence after surgical resection in patients with pathological stage I non-small cell lung cancer. Thorac Cardiovasc Surg. 2009;57(8):472-5.
III. Wahl M, Gubens MA, and Yom SS. Handbook of evidence-based radiation oncology. 3rd edition. Non-small Cell Lung Cancer, Eds Hansen EK, March Roach M. Springer International Publishing AG, pp 2018;293-322.
IV. Izbicki JR, Passlick B, Pantel K, Pichlmeier U, Hosch SB, Karg O, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg 1998;227:138–144.
V. The Lung Cancer Study Group. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 1988;6:9-17.
VI. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. http://seer.cancer. Gov/archive/csr/1975-2011, 2014.
VII. D Fang, D Zhang, G Huang, R Zhang, L Wang, D Zhang. Results of Surgical Resection of Patients With Primary Lung Cancer: A Retrospective Analysis of 1,905 Cases. Ann Thorac Surg 2001;72:1155–1159.
VIII. Yoshida Y, Murayama T, Sato Y, Suzuki Y, Saito H, Nomura Y. Gender Differences in Long-Term Survival after Surgery for Non-Small Cell Lung Cancer. Thorac Cardiovasc Surg 2016;64(6):507-14.
IX. Visbal AL, Williams BA, Nichols FC 3rd, Marks RS, Jett JR, Aubry MC, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004;78(1):209-215.
X. Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. US lung cancer trends by histologic type. Cancer 2014;120(18):2883–2892.
XI. Escuín JS, Sorribes ML, Arca JA, Ares AN, Hernández JH, Jover AMC, et al. The EpicliCP-2003 study: A multicenter epidemiological and clinical study of lung cancer in Spain. Arch Bronconeumol 2006;42:446-452.
XII. Fossella F, DeVore R, Kerr R, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-2362.
XIII. Saynak M, Aksu G, Fayda M, Kaytan E, Oral E, Gurocak S, et al. The results of concomitant and sequential chemoradiotherapy with cisplatin and etoposide in patients with locally advanced non-small cell lung cancer. J BUON 2005;10:213–218.
XIV. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008;3(1):46-52.
XV. 15. Loncarevic O, Acimovic S, Vukovic J, Stojisavljevic M, Maric N, Loncarevic S, et al. Overall survival of patients with non-small cell lung cancer after surgery treatment. Vojnosanit Pregl 2018;75(12):1157–1164.
XVI. Yoshino I, Yokoyama H, Yano T, Ueda T, Takai E, Mizutani K, et al. Comparison of the surgical results of lobectomy with bronchoplasty and pneumonectomy for lung cancer. J Surg Oncol 1997;64:32–35.
XVII. Suen HC, Meyers BF, Guthrie T, Pohl MS, Sundaresan S, Roper CL, et al. Favorable results after sleeve lobectomy or bronchoplasty for bronchial malignancies. Ann Thorac Surg 67;1999:1557–1562.
XVIII. Koike T, Terashima M, Takizawa T, Aoki T, Watanabe T, Akamatsu H. Results of surgery for primary lung cancer based on the new international staging system. Jpn J Thorac Cardiovasc Surg 1999;47:313–317.
XIX. Zarogoulidis K, Zarogoulidis P, Kaid Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 2013;5(4):389–396.
XX. Fukui T, Mori S, Yokoi K, T. Mitsudomi T. Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol 2006;2:120-125.
XXI. Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys 2008;72(3):695–701.
XXII. Munro AJ. What now for postoperative radiotherapy for lung cancer? Lancet 1998;25:352(9124):250-251.
XXIII. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III nonsmall-cell lung cancer using the Surveillance, Epidemiology, and End Results Database. J Clin Oncol 2006;24:2998-3006.
XXIV. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 2006;7:719-727.
XXV. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.